The recently discovered cytokine, interleukin-15 (IL-151, has been demonstrated to share several biologic properties with IL-2 in different cell systems, including T-cell and natural killer (NK) cell compartments. As for B lymphocytes, IL-15 has been shown to provide stimulatory activities in normal preactivated B cells that are mainly transduced through IL-2 receptor (IL-2R) complex components. Since leukemic B cells from patients with chronic lymphoproliferative disorders (CLD) bear IL-2R and grow in response to 11-2, we investigated whether IL-15 triggers the proliferation of malignant B cells obtained from 12 patients with B-cell chronic lymphocytic leukemia (B-CLL) and five patients with hairy cell leukemia (HCL). Enriched B cells recovered from five healthy subjects were also studied as controls. IL-15 stimulated the proliferation of freshly isolated leukemic B cells, but not resting normal B lymphocytes, the latter being able to grow in the presence of IL-15 only after in vitro preactivation with phorbol myristate acetate. The proliferation elicited by 11-2 on leukemic cells was comparable to that determined by ERIPHERAL B-CELL neoplasms are characterized by P the expansion and accumulation of monoclonal B lymphocytes frozen at a discrete stage of B-cell differentiation. Among this group, the most common disorder is chronic lymphocytic leukemia (B-CLL), which is characterized by the presence of relatively mature B lymphocytes expressing B-cell-related antigens and the CD5 surface molecule. Leukemic cells in this disorder have been observed to express several cytokine receptors, including interleukin-2 (IL-2), tumor necrosis factor (TNF), and CSF Following binding to relevant cytokines, these receptors may transduce signals that regulate the expression of other receptor structures and drive leukemic B-cell proliferation.6 IL-2 and its receptors have been demonstrated to play a central role in the mechanisms controlling the growth of neoplastic B cells!. '
The recently discovered cytokine, interleukin-15 (IL-151, has been demonstrated to share several biologic properties with IL-2 in different cell systems, including T-cell and natural killer (NK) cell compartments. As for B lymphocytes, IL-15 has been shown to provide stimulatory activities in normal preactivated B cells that are mainly transduced through IL-2 receptor (IL-2R) complex components. Since leukemic B cells from patients with chronic lymphoproliferative disorders (CLD) bear IL-2R and grow in response to 11-2, we investigated whether IL-15 triggers the proliferation of malignant B cells obtained from 12 patients with B-cell chronic lymphocytic leukemia (B-CLL) and five patients with hairy cell leukemia (HCL). Enriched B cells recovered from five healthy subjects were also studied as controls. IL-15 stimulated the proliferation of freshly isolated leukemic B cells, but not resting normal B lymphocytes, the latter being able to grow in the presence of IL-15 only after in vitro preactivation with phorbol myristate acetate. The proliferation elicited by 11-2 on leukemic cells was comparable to that determined by ERIPHERAL B-CELL neoplasms are characterized by P the expansion and accumulation of monoclonal B lymphocytes frozen at a discrete stage of B-cell differentiation. Among this group, the most common disorder is chronic lymphocytic leukemia (B-CLL), which is characterized by the presence of relatively mature B lymphocytes expressing B-cell-related antigens and the CD5 surface molecule. Leukemic cells in this disorder have been observed to express several cytokine receptors, including interleukin-2 (IL-2), tumor necrosis factor (TNF), and CSF Following binding to relevant cytokines, these receptors may transduce signals that regulate the expression of other receptor structures and drive leukemic B-cell proliferation.6 IL-2 and its receptors have been demonstrated to play a central role in the mechanisms controlling the growth of neoplastic B cells!. ' The IL-2 receptor (IL-2R) system is composed of three different membrane subunits: a (CD25, p55), p (CD122, p75), and y (p64) chains.'-I4 The different combination of these three membrane subunits results in low-, intermediate-, and high-affinity IL-2R. Both the a and p chains of the IL-2R are expressed on neoplastic B cells of patients with B-CLL and hairy cell leukemia (HCL), allowing them to proliferate in response to IL-2. '-3~15- 17 A novel cytokine, IL-15, has recently been identified in culture supematants of a monkey kidney epithelial cell line, CV-1EBNA.I' Although IL-15 shows no homology with IL-2, it does share some biologic effects with IL-2. In particular, IL-15 stimulates the proliferation of cytotoxic T-lymphocyte cell lines and phytohemagglutinin (PHA)-activated peripheral blood lymphocytes, induces natural killer (NK) cell activation, and promotes proliferation and differentiation of preactivated normal B cells.''-*' These two cytokines, at least in part, use components of the IL-2R system, ie, the p and y chains, for binding and signaling.
Although IL-15 shares several effects with IL-2 in different cell systems, including normal B cells, and although IL-2 is relevant for triggering leukemic B-cell growth and IL-15. Following addition of graded concentrations of 11-15 to lowlintermediate-dose IL-2, resting leukemic B cells showed a higher stimulatory rate than that observed using the two cytokines separately. In normal resting B lymphocytes, this cumulative effect was not observed. The role of different IL-2R subunits in IL-15-driven growth of malignant B cells was investigated both by their expression on leukemic cells and by the block of different IL-2R subunits (p55, p75, and p64) with specific monoclonal antibodies (MoAbs). Using flow cytometry and reverse transcriptase-polymerase chain reaction (RT-PCR) analyses we demonstrated that both B-CLL and HCL leukemic B cells express the /3 and y chains of the IL-2R system. The stimulatory activity achieved by IL-15 decreased significantly, blocking the /3 and y chains of the IL-2R. Taken together, these findings demonstrate that IL-15 triggers the growth of leukemic B cells through IL-2R system subunits, pointing to the role ofthis novel cytokine in regulating the neoplastic proliferation in CLD. 0 1996 by The American Society of Hematology.
regulating the expression of different receptor structures in B-CLL and HCL, no information is presently available regarding the effect of IL-15 on leukemic B lymphocytes. To investigate whether IL-15 displays stimulatory activity on neoplastic B cells from B-CLL and HCL patients, freshly purified leukemic and normal B lymphocytes were cultured in the presence of IL-15 and IL-2 in different experimental conditions. Data reported herein demonstrate that IL-15 triggers the proliferation of freshly isolated leukemic but not normal resting B lymphocytes, and that this function is transduced through components of the IL-2R system.
MATERIALS AND METHODS
Seventeen patients with different B-cell malignancies were studied 12 (eight men and four women aged 42 to 56 years) with B-CLL, and five (two men and three women aged 43 to 60) with HCL. B-CLL patients were graded according to the Rai staging system": stage 0 (six cases), stage I (four cases), and stage I1 (two cases). The total lymphocyte count ranged from 25,200 to 71,3201 pL. Leukemic B cells from these patients expressed B-cell-related antigens (CD19) and the CD5 molecule; they bore surface Igs at low density with a restriction for k light chain in seven patients and A light chain in five patients. In all HCL patients, leukemic B cells were detected in the peripheral blood, with a hairy cell number ranging from 2,520 to 10,65O/pL. The diagnosis was established on the basis of clinical, morphologic, cytochemical, histologic, and immunologic features, as previously described. Is All these patients had the classic form of the disease. In fact, hairy cells expressed the immunologic pattern of typical HCL (CD19, CD103, CD2.5, and CDI IC), as well as the positivity for tartrate-resistant acid phosphatase (TRAP). None of the patients had any therapy before the study.
Peripheral blood lymphocytes (PBL) from patients under study were obtained from freshly heparinized blood by centrifugation on a Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient.' Normal B lymphocytes were derived from the spleen of five normal subjects who experienced a posttraumatic splenectomy. After mechanic disruption, spleen cells were centrifuged through a Ficoll-Hypaque gradient. The cells were then washed three times with phosphate-buffered saline (PBS) and resuspended in RPMI 1640 medium (GIBCO, Paisley, Scotland). All samples tested were fresh material.
The samples were enriched for B lymphocytes using a modification of the method previously described.' Following removal of Erosetting cells by the neuraminidase (Sigma Chemical Co, St Louis, M0)-treated sheep red blood cell rosetting technique, the cell suspension was depleted of adherent cells by incubation for 45 minutes in plastic Petri dishes at 37°C in an atmosphere of 95% air and 5% CO,. Using the method of Lea et al,2' cells were further purified by removing CD3+ and CD56+ lymphocytes using magnetic microspheres coated with antimouse IgG (Dynebeads, Dynal, Norway), as previously described in detail.' Briefly, after incubation (45 minutes at 4°C) of the cell suspension obtained as above with CD3 (OKT3; Ortho, Raritan, NJ) and CD56 (Leu 19; Becton Dickinson, Sunnyvale, CA) monoclonal antibodies (MoAbs), 40 X 10' beads were incubated with IO X 10' cells/mL for 30 minutes at 4°C under continuous slow rotation. The CD3+ and CD56+ cells rosetting with antibody-coated beads were then isolated and removed by applying a magnetic system on the outer wall of the test tubes for 2 minutes.
Following this multistep negative-selection procedure, greater than 97% of cells were viable as judged by the trypan blue exclusion test. More than 95% of cells were found to be CD19'KDS-in normal enriched B-cell suspensions, 99% were CDI9+/CDSt in B-CLL-enriched cells, and 94% were CDI 9 '/CD103'/CD25+/ CDI IC+ in HCL-enriched populations.
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sis, 1 X cells were acquired, and the analysis was determined by overlaying the histograms of samples stained with the different reagents. Cells were scored using a FACScan analyzer (Becton Dickinson), and data were processed by CONSORT 30 or Lysys software programs (Becton Dickinson). To evaluate whether differences between cell peaks were statistically significant with respect to control values, the Kolmogorov-Smirnov test for histogram analysis was used according to the CONSORT 30 software user's guide (Becton Dickinson).
RNA extraction, cDNA synthesis, und polymerase chain reaction ampl$cation of IL-2R subunits. Total cellular RNA was extracted using the ultraspec-I1 RNA isolation system (Biotecx Laboratory, Houston, TX) from purified leukemic cells (>99% CD19' lymphocytes) and PHA (5 pglmL)-stimulated PBL. cDNAs were prepared from 2 pg total cellular RNA by reverse transcriptase (RT) at 42°C for 30 minutes in a 20-pL reaction. cDNA was synthesized in the presence of Moloney murine leukemia virus RT (2.5 U), using 2 3 p,moUL oligo-d(T) primer and reaction conditions described by the manufacturer (Invitrogen Corp, San Diego, CA). The reaction was stopped by heating the sample to 99°C for 5 minutes.
For the a and P chain of 1L-2R, 5 pL cDNA was amplified in a volume of SO pL and in the presence of 40 pmol/L specific primers (Clontech Laboratory, Palo Alto, CA), which yield a band of 398 and 374 bp, respectively. The polymerase chain reaction (PCR) mixture consisted of 1.5 mmollL MgCI2, SO mmoVL KCI, IO mmol/L TI+-hydrochloride, 0.2 mmoVL of each deoxynucleotide triphosphate, and 2.5 U Taq polymerase (Perkin Elmer, Nonvalk, CT). Reaction conditions were 45 seconds of melting at 94°C. 45 seconds of annealing at 60"C, and 120 seconds of extension at 72°C for 30 cycles followed by a final extension for 7 minutes at 72°C in a Cetus/Perkin Elmer thermal cycler. For the y chain of L 2 R , 1 pL cDNA was amplified in a total volume of SO pL in the presence of 25 pmol/L of each oligonucleotide (5'-TATAGGATCCGAAGAGCAAGC-GCCATGTTGAAGCC and 3'-AGATTCTGCAGTTTTAGCATC-TGTGTGGCC) according to published sequencing data," which yield a band of 45 I bp. The reaction mixture was similar to that for the a and p chain, but contained 2.5 m m o m MgC12. Reaction conditions were I minute of melting at 94"C, 1 minute of annealing at 52"C, and 2 minutes of extension at 72°C for 30 cycles followed by a final extension of 7 minutes at 72°C. For control, p-actin gene was amplified from 2 pL cDNA in a total volume of 50 pL in the presence of 25 pmollL of the following oligonucleotide (5'-GTGGGGCGCCCCAGGCACCA and 3'-CTCCTTAATGTCACG-CACGATTTC), which yields an amplification product of 540 bp.'" The reaction mixture was similar to that used for the y chain. Reaction conditions were 1 minute of melting at 94"C, 1 minute of annealing at SYC, and 2 minutes of extension at 72°C for 30 cycles followed by a final extension of 7 minutes at 72°C. Twenty microliters of PCR product was electrophoresed in a 2% agarose gel in TrisborateEDTA buffer. Gels were stained with ethidium bromide and photographed. To avoid contamination, reagent controls were performed.
Purified and freshly isolated normal and leukemic B lymphocytes were cultured in 96 round-bottom well plates (Tirtetek; ICN, Oxnard, CA) in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS; ICN), penicillin (100 UlmL), and streptomycin (50 mglmL). Preactivated B cells were obtained following in vitro culture with PMA (IO ng/mL; Sigma) for 24 hours. After this incubation, cells were washed and successively cultured with IL-2 or IL-15. Cultures were performed in triplicate, with each well containing 1 x 10' cells in 0.2 mL medium, and then incubated for 5 days at 37°C in a humidified atmosphere of 5% CO? and 95% air. Cytokines were added in different concentrations at the beginning of the culture. IL-2 was used as follows: I, 10, 100, and I ,OOO U/mL IL-l 5 at 0.1, I , 10, and 100 ng/mL. To investigate a cooperative effect of the above-mentioned cytokines on B cells, graded concentrations of IL-15 (0.1, 1, 10, and 100 ng/mL) were added to fixed doses of L-2 (10, 100, 1,000 U/&).
The effect of different L-2R subunits on L-2-and IL-15-induced proliferation of leukemic B cells was examined following blocking of the p55, p75, and p64 subunits with specific antibodies recognizing these three different chains, including anti-Tac (10 pg/ mL), TU27 (10 pg/mL), and TUGh4 (10 pg/mL), respectively. Purified leukemic B cells were preincubated with the above-mentioned MoAbs at 4°C before adding the cytokines. Control isotype antibodies (mouse IgGZa for anti-Tac, mouse IgGl for TU27, and rat IgG2b for TUGh4) were used. Proliferation was determined by pulsing plates with 'H-thymidine (1 pCi per well; CEA Ire Sorin, Saluggia, Italy) for the last 12 hours of culture; cells were then harvested, and 'H-thymidine incorporation was measured in a 0-scintillation counter.
Statistical analysis. Results are expressed as counts per minute ([cprn] mean -C SD) or stimulation index (SI) according to the following formula: mean cpm stimulated celldmean cpm cultured cells in medium alone. SI is reported as the mean ? SD, and comparisons between values were made using the f test. A P value less than .05 was considered significant. 18.5 t 3.2 at 0.1, 1, 10, and 100 ng/mL, respectively. The difference between leukemic and normal B-cell proliferation was statistically significant at high concentrations of IL-15 (P < .05 at 10 ng/mL and P < .005 at 100 ng/mL). IL-15 triggering of resting normal B cells did not reach values higher than 2.1 ? 0.5 at 100 ng/mL. The actual cpm of 3H-thymidine incorporation from these experiments are reported in Table 1 .
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RESULTS
Effect
As for the ability of leukemic B cells to proliferate to IL-2, we observed (Fig 1B) that IL-2 is able to induce proliferation of freshly isolated neoplastic B cells. The higher proliferative rate was achieved when high concentrations of IL-2, ie, 100 and 1,000 U/mL, were used. SI values were 1.3 ? 0.5, 3.3 t 1.7, 6.7 t 1.4, and 19.9 IfI 1.9 at 1, 10, 100, and 1,000 U/mL IL-2. Low proliferative values were obtained in normal B cells cultured at either low or high concentrations of IL-2. A statistically significant difference was observed between resting neoplastic and normal B lymphocytes at 1,000 U/mL IL-2 (P < .005).
The proliferation of neoplastic B lymphocytes induced by IL-15 and IL-2 was approximately superimposable in the two groups of patients, ie, B-CLL and HCL. One representative patient from each group is reported in Fig 2, indicating that IL-15-and IL-2-induced leukemic growth was similar in these two patients.
We subsequently examined the effect of the combination of IL-2 and IL-15 on freshly isolated leukemic and normal B lymphocytes. B cells were cultured in the presence of fixed concentrations of IL-2 (10, 100, and 1, OOO U/mL) and graded concentrations of IL-15 (0, 0.1, 1, 10, and 100 ng/ mL). Figure 3 shows data obtained in patients with chronic For lymphoproliferative disorders (CLD) and normal subjects. Proliferation rates achieved in patients under study following in vitro stimulation with IL-2 ranged from 2.7 ? 1.3 to 18.3 ? 3.9. At the fixed IL-2 concentration of 10 and 100 U/ m L , we observed an increase in B-cell growth after adding increasing doses of IL-15 to the culture. When high concentrations of IL-2 (1,000 U/mL) were used, the proliferation elicited by IL-2 was not significantly modified by addition of IL-15. As for normal B cells, low proliferation rates were observed in the presence of the combinations of IL-15 and IL-2. To further saturate receptors, in three B-CLL patients, higher concentrations of IL-2 (ie, 10,000 U/mL) and IL-15 (1,000 ng/mL) were used. Data related to these experiments are reported in Table 2 , which demonstrate that with high concentrations of IL-2 (10,000 U/mL) the proliferation curve reached a plateau, thus indicating that IL-15 had no additive effect on IL-2-driven proliferation. Similar results were obtained when leukemic B cells were cultured with high concentrations of IL-15 (1,000 ng/mL) and increasing doses of IL-2. .-$ .. When IL-15 was investigated for the ability to trigger the proliferation of normal B lymphocytes, an increased proliferation rate was observed only in PMA-preactivated cells as compared with unstimulated B cells (Fig 4C) , with P less than .05 and P less than .005 at 10 and 100 ng IL-WmL. IL-2 was also able to induce proliferation of PMA-preactivated normal B lymphocytes (Fig 4D) rather than normal B cells cultured in medium alone ( P < .05). The relationship between the proliferation shown by IL-2 and its receptors was analyzed using the same experimental design. Preincubation of tumor B lymphocytes with anti-p55 MoAb considerably inhibited IL-2-driven proliferation at both low and high IL-2 concentrations. A similar inhibitory effect was observed when neoplastic B cells were preincubated with anti-p75 MoAb. Blocking of the p64 IL-2R chain induced a lower inhibitory effect with respect to anti-p55 and anti-p75 MoAbs. The combination of anti-p75 and anti- p64 MoAbs, as well the combination of anti-p55, anti-p75, and anti-p64 MoAbs (data not shown), almost completely blocked IL-2-driven proliferation of tumor B cells. Because of the inhibitory effect of anti-IL-2R MoAbs on IL-15-and IL-2-driven cell proliferation in neoplastic Bcell disorders, the IL-2R chain expression was analyzed by both flow cytometry analysis and RT-PCR. The phenotypic profile in three representative patients (two B-CLL and one HCL) is reported in Fig 6. Both B-CLL and HCL freshly isolated leukemic B cells bear the three different subunits of the IL-2R system at resting conditions. Although the a chain is clearly expressed on these cells, its intensity is higher in HCL than in B-CLL. The p and y subunits are expressed at low density on neoplastic cells of these patients. Using the Kolmogorov-Smimov test, the shift of histograms related to these latter molecules was statistically significant with respect to control histograms. To further validate this pattern of IL-2R expression, RT-PCR analysis of different IL-2R chains was performed (Fig 7) . This analysis showed that leukemic cells belonging to B-CLL and HCL patients express detectable messages for these molecules. The intensity of IL-2R a chain is qualitatively higher in HCL than in B-CLL.
Relationship between IL-2R and IL-
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DISCUSSION
In this study, we demonstrated that the novel cytokine, IL-15, is able to trigger the proliferation of freshly isolated leukemic B cells obtained from patients with CLD, whereas resting normal B lymphocytes are unresponsive to this molecule. This proliferative effect was increased by addition of IL-2 to the culture. To investigate the receptor structure involved in IL-15-driven B-cell proliferation, experiments were also performed in the presence of IL-2 or IL-15 following blocking of different IL-2R subunits by specific MoAbs.
We demonstrated that both the p and y chains of the IL-2R system are expressed on B-CLL and HCL leukemic cells and are involved in IL-2-and IL-15-driven B-cell proliferation.
The capability shown herein of IL-15 to promote in vitro growth of malignant B cells represents the first demonstration that this cytokine has a stimulatory function on leukemic B cells, thus extending previous observations limited to normal lymphocytes. In particular, IL-15 interaction with normal lymphocytes results in induction of growth and differentiation on B cells, and proliferation and LAK activity generation on NK Our experiments clearly demonstrate that this molecule is able to transduce a proliferative signal on freshly isolated leukemic B lymphocytes recovered from patients with B-cell malignancies, ie, B-CLL and HCL. This finding represents a discrete feature that distinguishes leukemic B cells from normal CD5-B lymphocytes. In fact, IL-15 triggering of normal CD5-B lymphocytes results in a significant growth only following in vitro polyclonal preactivation, such as with PMA" (and our data). Whether differences in B-cell response to IL-15 exist among subsets of B Log. Fluorescence intensity lymphocytes (ie, CD5-and CDS' cells) still remains to be elucidated. In this regard, the cell source to obtain enough nonneoplastic CD5' B lymphocytes to assess in vitro studies is represented by the tonsil, an organ that is commonly exposed to a great variety of foreign stimuli that can determine an activation state and priming of CDS' B cells. This, of course, represents a bias that prevents evaluation of this issue.
Several mechanisms might account for the particular responsiveness of leukemic B cells to IL-15. One possibility deals with the ability of these malignant R cells to hear 1L-15 binding sites on their surface membrane. In this regard, it has been reported that leukemic B cells from B-CLL and HCL patients express IL-2 binding moleculesl~g.'s~lh known to be shared by IL-15. Secondly, it is known that tumor Bcell triggering of IL-2Rs might result in a variety of events, including upregulation of different receptor structures and probably of cytokines that might have relevance in leukemic cell growth.' In this regard, IL-15 is able to trigger the production of several cytokines. including IFN-y, TNF-a, and GM-CSF on NK cells when combined with IL-12 and TNFcy."' Whether similar mechanisms act in B-cell malignancies, in particular B-CLL and HCL, remains to be investigated. Although these two disorders show differences in terms of both clinical features and phenotypic profile, IL-15-mediated proliferation was detected in both diseases. This observation suggests that leukemic cell proliferation was probably For personal use only. on August 30, 2017. by guest www.bloodjournal.org From better related to the presence of a receptor structure (IL-2R subunits) that is fully functional to transduce stimulatory signals, rather than to differences in terms of B-cell subsets.
Looking at the proliferative activity induced by IL-15, we observed that this proliferation was more effective when high concentrations of IL-15 were used and when leukemic cells were preactivated in vitro with PMA. These findings indicate that neoplastic B cells require high concentrations of IL-15 for proliferation. A similar pattern was also reported in normal B and NK cells, where considerable rates may be achieved at concentrations of 10 and 100 ng IL-15/mL.2032' Following in vitro preactivation of neoplastic B cells with PMA, we observed an increased proliferative response to IL-2 rather than to IL-15. This finding might be interpreted as the consequence of an upregulation of cytokine binding sites for IL-2 rather than for IL-15 on these cells.
Since IL-15 shares biologic properties with IL-2, we performed proliferative tests by culturing neoplastic B cells with different combinations of these cytokines. We demonstrated that IL-15 induces an increase in IL-2-driven B-cell growth, possibly as a consequence of a cumulative effect displayed by these two cytokines on neoplastic B lymphocytes. Alternatively, this finding might represent the result of a nonsaturating effect of IL-2 on these cells. In accordance with this last interpretation, the most pronounced cumulative effect was observed (Fig 3 and Table 2 ) when low or intermediate concentrations of IL-2, such as 10 and 100 U IL-2/mL, were used. A putative regulation of IL-2 binding sites by IL-15 might also be taken into account in the mechanisms determining this additive effect.
The recent demonstration that this novel cytokine shows overlapping activities with IL-2 was recently investigated in normal peripheral blood mononuclear cells by Gin et al,I9
who reported that the 0 and y subunits of the IL-2R system are required for the binding of IL-15 and signal transduction. The evidence we provided that the blocking of the p55 chain of IL-2R, which is expressed on neoplastic B cells from both B-CLL and HCL patients, inhibits IL-2-but not IL-15-mediated proliferation (Fig 5) confirmed the report" in terms of the irrelevant role of this subunit in IL-15 binding. Furthermore, our data suggest that also in cells belonging to the B-cell lineage, IL-15 transduces proliferative signals following binding to the and y subunits of the IL-2R system.
Since malignant B cells bear the 0 and y chains of IL-2R, as demonstrated by phenotypic and molecular analyses ( Figs  6 and 7) , to verify the above hypothesis, we performed proliferation assays in the presence of antibodies blocking the p and y chains of IL-2R. The data herein reported indicate that both chains are involved in IL-15 triggering of leukemic B cells, since the distinct occupancy of these two subunits resulted in a reduction of IL-15 -mediated proliferation.
Although the 0 and y chains are mainly involved in transduction of the IL-15-triggered signal, the presence of these two chains does not guarantee IL-15-responsiveness. In fact, it has been demonstrated that the murine cell line, 32D, that constitutively expresses the and y chains of the IL-2R proliferates in response to IL-2 but not to IL-15.I9 This finding suggests that the IL-15 receptor structure may be formed by molecules that are shared with receptors for other cytokines (0 and y chains) and a subunit that is specific for IL-15, similar to the a chain of IL-2R. In this regard, an IL-15 receptor, designated IL-15Ra for analogy with the a chain of IL-2R (IL-2Ra), has been identified in mice, and a chains of IL-2 and IL-15 receptors have been suggested to define a novel family of receptors for cytokines.*' Likewise, the y chain of IL-2R is known to represent the component of receptors for other cytokines, including IL-4, IL-7, IL-9, and IL-13, IL-15,'9,25,27-29 and to trigger different functions in lymphocytes that are not dependent on the pathway used for transduction of the signal but are related to the binding molecule or cytokine. Our observation that simultaneous blocking of the ,f? and y subunits almost abrogated IL-15 -induced proliferation of neoplastic B cells indicates that the mechanism quoted above might represent the preferential route used by this novel cytokine to transduce proliferation signals in cells from patients with CLD. Further investigations on the interrelationships between IL-15 and other cytokines and their own receptors, as well as on the cell source for this novel cytokine, will yield new insights into the mechanisms regulating IL-15-mediated leukemic growth.
